Cart
sales@molnova.com
Letrozole
CAS No. 112809-51-5
Letrozole( CGS 20267 )
Catalog No. M10447 CAS No. 112809-51-5
Letrozole (INN, trade name Femara) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast Y Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 29 | In Stock |
|
| 50MG | 43 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLetrozole
-
NoteResearch use only, not for human use.
-
Brief DescriptionLetrozole (INN, trade name Femara) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast Y Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme.
-
DescriptionLetrozole (INN, trade name Femara) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast Y Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. (In Vitro):Letrozole (0.1-100 nM; 24-96 h) significantly inhibits growth of the MCF-7 epithelial breast cancer cells in a dose- and time-dependent manner.Letrozole (10 nM) significantly suppresses the stimulatory effects of testosterone on MCF-7 cell proliferation.Letrozole (10 nM; 24-48 h) suppresses the levels of secreted metalloproteinases (MMP‐2 and MMP‐9) in MCF-7 cells(In Vivo):Letrozole (3-300 μg/kg; oral gavage once daily for 6 weeks) exhibits anti-tumor effects in rats.
-
In VitroLetrozole (0.1-100 nM; 24-96 h) significantly inhibits growth of the MCF-7 epithelial breast cancer cells in a dose- and time-dependent manner.Letrozole (10 nM) significantly suppresses the stimulatory effects of testosterone on MCF-7 cell proliferation.Letrozole (10 nM; 24-48 h) suppresses the levels of secreted metalloproteinases (MMP‐2 and MMP‐9) in MCF-7 cells. Cell Viability Assay Cell Line:MCF-7 cells Concentration:0.1, 1, 10, 100 nM Incubation Time:24, 48, 96 hours Result:Inhibited cells growth in a dose- and time-dependent manner.
-
In VivoLetrozole (3-300 μg/kg; oral gavage once daily for 6 weeks) exhibits anti-tumor effects in rats. Animal Model:Adult female rats bearing mammary tumorsDosage:3, 10, 30, 100, 300 μg/kg Administration:Oral gavage once daily for 6 weeks Result:Induced complete regression of mammary tumors, with an ED50 of 10-30 μg/kg/day.
-
SynonymsCGS 20267
-
PathwayEndocrinology/Hormones
-
TargetAromatase
-
RecptorAromatase
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number112809-51-5
-
Formula Weight285.3
-
Molecular FormulaC17H11N5
-
Purity>98% (HPLC)
-
SolubilityDMSO: 57 mg/mL (199.78 mM)
-
SMILESN#CC1=CC=C(C(C2=CC=C(C#N)C=C2)N3N=CN=C3)C=C1
-
Chemical Name4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Haynes BP, et al. J Steroid Biochem Mol Biol, 2003, 87(1), 35-45.
molnova catalog
related products
-
Anastrozole
Anastrozole(ZD1033) is a potent and highly selective aromatase (CYP19) inhibitor (IC50 = 15 nM) .
-
Flavokawain A
Flavokawain A has anti-tumor activity, such as inhibits growth of bladder tumor cells in a nude mice model , prevents the recurrence and progression of non-muscle-invasive urothelial cell carcinoma.
-
Formestane
Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast Y in post-menopausal women.
